JP2021503490A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503490A5
JP2021503490A5 JP2020543658A JP2020543658A JP2021503490A5 JP 2021503490 A5 JP2021503490 A5 JP 2021503490A5 JP 2020543658 A JP2020543658 A JP 2020543658A JP 2020543658 A JP2020543658 A JP 2020543658A JP 2021503490 A5 JP2021503490 A5 JP 2021503490A5
Authority
JP
Japan
Prior art keywords
compound according
compound
formula
derivative
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503490A (ja
JP7282792B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2018/051336 external-priority patent/WO2019075583A1/en
Publication of JP2021503490A publication Critical patent/JP2021503490A/ja
Publication of JP2021503490A5 publication Critical patent/JP2021503490A5/ja
Priority to JP2023081323A priority Critical patent/JP7592120B2/ja
Application granted granted Critical
Publication of JP7282792B2 publication Critical patent/JP7282792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543658A 2017-10-22 2018-10-22 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物 Active JP7282792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081323A JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575460P 2017-10-22 2017-10-22
US62/575,460 2017-10-22
PCT/CA2018/051336 WO2019075583A1 (en) 2017-10-22 2018-10-22 NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081323A Division JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Publications (3)

Publication Number Publication Date
JP2021503490A JP2021503490A (ja) 2021-02-12
JP2021503490A5 true JP2021503490A5 (cg-RX-API-DMAC7.html) 2021-12-02
JP7282792B2 JP7282792B2 (ja) 2023-05-29

Family

ID=66173073

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543658A Active JP7282792B2 (ja) 2017-10-22 2018-10-22 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物
JP2023081323A Active JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081323A Active JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Country Status (8)

Country Link
US (2) US20200339625A1 (cg-RX-API-DMAC7.html)
EP (1) EP3700917A4 (cg-RX-API-DMAC7.html)
JP (2) JP7282792B2 (cg-RX-API-DMAC7.html)
KR (1) KR102884167B1 (cg-RX-API-DMAC7.html)
CN (1) CN111630059B (cg-RX-API-DMAC7.html)
AU (1) AU2018352731B2 (cg-RX-API-DMAC7.html)
CA (1) CA3079906A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019075583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
DK3498308T3 (da) 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid
CA3136979A1 (en) * 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
CN110317151B (zh) * 2019-06-06 2022-06-24 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-HBBED-ANCP-PSMA及其制备方法和应用
WO2020252598A1 (en) * 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
TWI908773B (zh) * 2020-03-04 2025-12-21 日商日本醫事物理股份有限公司 化合物及放射性標誌化合物
US20240018110A1 (en) * 2020-12-16 2024-01-18 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2022167681A1 (en) * 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
US20240174622A1 (en) 2021-03-04 2024-05-30 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
JP2024532521A (ja) 2021-09-03 2024-09-05 晶核生物医藥科技(南京)有限公司 ペプチド-尿素誘導体、それを含む医薬組成物、及びそれらの使用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
WO2023083209A1 (zh) * 2021-11-10 2023-05-19 苏州瑞核医药科技有限公司 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
EP4436979A4 (en) 2021-11-26 2026-06-10 Full Life Tech Uk Limited Cleftable radioligands for targeting cell surface receptors and their uses
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
TW202410923A (zh) * 2022-09-09 2024-03-16 大陸商同宜醫藥(蘇州)有限公司 放射性核種偶聯藥物及其藥物組成物和應用
CN116199736B (zh) * 2023-03-01 2025-03-18 西南医科大学附属医院 一种DOTA-Te-PSMA化合物及其应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
US20250213705A1 (en) 2023-08-23 2025-07-03 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3400229B1 (en) 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
CN109982998A (zh) * 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2012511023A5 (cg-RX-API-DMAC7.html)
JP2020518674A5 (cg-RX-API-DMAC7.html)
JP7630149B2 (ja) Psmaを標的としたイメージング及び放射線治療のための金属/放射性金属標識psma阻害剤
RU2019139432A (ru) Фармакокинетическая оптимизация бифункциональных хелатов и их применение
RU2019139434A (ru) Моноклональные антитела против igf-1r и их применение
JP2833766B2 (ja) アミノポリカルボン酸およびその誘導体
JP2010523599A5 (cg-RX-API-DMAC7.html)
JP2024536362A5 (cg-RX-API-DMAC7.html)
JP2020520902A5 (cg-RX-API-DMAC7.html)
RU2011127467A (ru) Са-ix специфические радиофармпрепараты для лечения и визуализации злокачественных опухолей
JP2021502358A5 (cg-RX-API-DMAC7.html)
JP2016500107A5 (ja) グルタミナーゼ阻害剤およびその使用方法
JP7438756B2 (ja) In situ免疫調節癌ワクチン接種のための標的化された放射線治療用キレート
JP2010533727A5 (cg-RX-API-DMAC7.html)
JP2013533228A5 (cg-RX-API-DMAC7.html)
JP2012533523A5 (cg-RX-API-DMAC7.html)
JP2022509220A5 (ja) 腫瘍抗原標的化剤、医薬組成物、癌診断薬又は癌治療薬、in vitro法、及びその化合物
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2021502368A (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法(trt)の使用
JP2016521275A5 (cg-RX-API-DMAC7.html)
JP2024544870A5 (cg-RX-API-DMAC7.html)
JP2022517730A5 (cg-RX-API-DMAC7.html)
JP2004532820A (ja) 標的放射線療法のためのアクチニウム−225錯体および複合体
RU2018126958A (ru) Кфтр регуляторы и способы их применения
JP2008534558A5 (cg-RX-API-DMAC7.html)